Settings for recombinant adenoviral-based vaccines
AssigneeCrucell Holland B.V.
InventorsMenzo Jans Havenga, Lennart Holterman, Stefan Kostense, Maria Grazia Pau, Mieke C. Sprangers, Ronald Vogels
Life of this patent
Estimating the term…
Abstract
The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.
Claims5
An improvement in a method of delivering a nucleic acid sequence of interest to a subject using an adenoviral delivery vehicle, the method comprising:
- administering to the subject a recombinant adenovirus vector of Ad35 serotype having a nucleic acid sequence encoding a malaria antigen;
- and
- administering to the subject, subsequent to administering the recombinant adenovirus vector of the Ad35 serotype, a recombinant adenovirus vector of Ad5 serotype having a nucleic acid sequence encoding essentially the same malaria antigen.
A method of delivering a nucleic acid sequence encoding a malaria antigen to a subject, the method comprising:
- administering a recombinant adenovirus vector of Ad5 serotype to a subject previously administered a recombinant adenovirus vector of Ad35 serotype, wherein the recombinant adenovirus vector of Ad35 serotype and the adenovirus vector of Ad5 serotype each comprise a nucleic acid sequence encoding essentially the same malaria antigen.
A method of delivering a nucleic acid sequence encoding a malaria antigen to a subject, the method comprising:
- screening a human or animal for the presence of neutralizing antibodies against an adenovirus of Ad35 serotype;
- and
- administering a recombinant adenovirus vector of Ad35 serotype encoding a malaria antigen and subsequently with a recombinant adenovirus of Ad5 serotype encoding essentially the same malaria antigen.
A method of delivering a nucleic acid sequence encoding a malaria antigen to a subject, the method comprising:
- administering a recombinant adenovirus vector of Ad5 serotype to a subject previously administered a recombinant adenovirus vector of Ad35 serotype, wherein the recombinant adenovirus vector of Ad35 serotype and the adenovirus vector of Ad5 serotype each comprise a nucleic acid sequence encoding an identical malaria antigen.
A method of delivering nucleic acid sequences encoding a malaria antigen to a subject, the method comprising:
- screening a subject for the presence of neutralizing antibodies against an adenovirus of Ad35 serotype;
- administering to the subject a recombinant adenovirus vector of Ad35 serotype comprising a nucleic acid sequence encoding the malaria antigen;
- and,
- subsequent thereto, administering to the subject a recombinant adenovirus of Ad5 serotype comprising a nucleic acid sequence encoding the malaria antigen,
- so as to deliver the nucleic acid sequences encoding the malaria antigen to a subject.
Dependencies are inferred from the claim text.